Immuron Limited - American Depositary Shares (IMRN)
1.8000
+0.6900 (62.16%)
NASDAQ· Last Trade: Sep 4th, 10:32 PM EDT
Detailed Quote
Previous Close
1.110
Open
1.810
Bid
1.680
Ask
1.690
Day's Range
1.540 - 1.990
52 Week Range
0.6765 - 2.390
Volume
123,135,249
Market Cap
320.90M
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
5,350,335
Chart
About Immuron Limited - American Depositary Shares (IMRN)
Immuron Ltd is a biotechnology company focused on developing and commercializing innovative immunotherapeutic products aimed at treating various diseases, primarily those associated with the immune system and gastrointestinal health. The company uses its proprietary technology to create therapeutic agents that target specific pathways related to immune response, with applications in conditions such as traveler's diarrhea, inflammatory bowel disease, and other inflammatory disorders. Immuron is dedicated to advancing its research and development efforts to improve patient outcomes through targeted therapies that leverage the body's immune mechanisms. Read More
Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular session. The market value of their outstanding shares is at $8.9 million. bioAffinity Technologies (NASDAQ:BIAF) shares
Gainers Immuron (NASDAQ:IMRN) stock increased by 64.9% to $1.83 during Friday's pre-market session. The company's market cap stands at $8.9 million. Akanda (NASDAQ:AKAN) shares increased by 27.52% to $4.68.
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.
MELBOURNE, Australia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026.
MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on Monday, 20th July 2026 (12:30pm Australian Eastern Time).
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2026 / Emerging Growth Research today released a Flash Report on Immuron (Nasdaq:IMRN), maintaining its Buy-Extended rating while increasing its 12-month price target to $4.00 (from $3.90), representing significant upside from the current share price of $0.9268 as of April 21, 2026.
NEW YORK CITY, NEW YORK / ACCESS Newswire / March 5, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.90 following the Company's release of first-half fiscal year 2026 financial results and strategic update.
MELBOURNE, Australia, March 05, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Coffee Microcaps Conference on Thursday 5th March 2026 (11:00am – 11:30am Australian Eastern Time).
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.50 following the Company's release of first-half fiscal year 2026 operating results.
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.
Immuron Limited (NASDAQ: IMRN) experienced a significant downturn in its stock performance today, December 3, 2025, with shares plummeting by a notable -12.05 percent. This sharp decline is largely attributed to a confluence of factors, primarily anxieties stemming from an unconfirmed management shake-up and a generally pessimistic market outlook
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
